Zhejiang Jiuzhou Pharmaceutical Co Ltd banner
Z

Zhejiang Jiuzhou Pharmaceutical Co Ltd
SSE:603456

Watchlist Manager
Zhejiang Jiuzhou Pharmaceutical Co Ltd
SSE:603456
Watchlist
Price: 16.54 CNY -2.36% Market Closed
Market Cap: ¥14.7B

Zhejiang Jiuzhou Pharmaceutical Co Ltd
Total Liabilities & Equity

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Zhejiang Jiuzhou Pharmaceutical Co Ltd
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Z
Zhejiang Jiuzhou Pharmaceutical Co Ltd
SSE:603456
Total Liabilities & Equity
¥10.7B
CAGR 3-Years
11%
CAGR 5-Years
17%
CAGR 10-Years
15%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Liabilities & Equity
¥39.9B
CAGR 3-Years
10%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Liabilities & Equity
¥69.9B
CAGR 3-Years
18%
CAGR 5-Years
15%
CAGR 10-Years
20%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Liabilities & Equity
¥54.3B
CAGR 3-Years
1%
CAGR 5-Years
0%
CAGR 10-Years
11%
Zhejiang Nhu Co Ltd
SZSE:002001
Total Liabilities & Equity
¥45.6B
CAGR 3-Years
6%
CAGR 5-Years
8%
CAGR 10-Years
17%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Total Liabilities & Equity
¥7.1B
CAGR 3-Years
96%
CAGR 5-Years
46%
CAGR 10-Years
N/A
No Stocks Found

Zhejiang Jiuzhou Pharmaceutical Co Ltd
Glance View

Market Cap
14.7B CNY
Industry
Pharmaceuticals

Founded in 1973, Zhejiang Jiuzhou Pharmaceutical Co. Ltd. has steadily navigated the evolving tides of the global pharmaceutical industry with a compelling blend of innovation and traditional business acumen. Rooted in China's dynamic Zhejiang province, the company initially focused on manufacturing basic pharmaceutical intermediates. Over the years, it strategically expanded its operations, becoming a key player in both the Active Pharmaceutical Ingredients (APIs) and Contract Development and Manufacturing Organization (CDMO) sectors. This dual focus has allowed Jiuzhou Pharmaceutical to innovate and offer comprehensive services, ranging from drug development to commercial manufacturing, effectively appealing to a broad range of customers including some of the world's leading pharmaceutical companies. At the heart of Jiuzhou Pharmaceutical's success lies its commitment to research and development, a cornerstone that supports its diversification strategy. The company leverages its extensive expertise and cutting-edge technology to improve existing drugs while also participating in the development of new, patented pharmaceuticals. By fostering strong partnerships with global pharmaceutical giants, Jiuzhou effectively integrates itself into the larger pharmaceutical ecosystem, providing customized solutions that resonate with market demand. This business model not only reinforces its financial growth but also establishes Zhejiang Jiuzhou as an indispensable contributor to advancements in medicine, continually enhancing its reputation on the international stage.

Intrinsic Value
22.79 CNY
Undervaluation 27%
Intrinsic Value
Price ¥16.54
Z

See Also

What is Zhejiang Jiuzhou Pharmaceutical Co Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
10.7B CNY

Based on the financial report for Sep 30, 2025, Zhejiang Jiuzhou Pharmaceutical Co Ltd's Total Liabilities & Equity amounts to 10.7B CNY.

What is Zhejiang Jiuzhou Pharmaceutical Co Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
15%

Over the last year, the Total Liabilities & Equity growth was -3%. The average annual Total Liabilities & Equity growth rates for Zhejiang Jiuzhou Pharmaceutical Co Ltd have been 11% over the past three years , 17% over the past five years , and 15% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett